Venlafaxine 25 mg Immediate Release Tablets — Generic For Effexor — TEVA

Medication Summary

Medication Summary: This section summarizes DailyMed drug label information to make the label easier to understand. It is not a substitute for the official label, pharmacist counseling, prescriber instructions, or medical advice.

Overview

Venlafaxine tablets, USP are a prescription antidepressant made by Teva Pharmaceuticals USA, Inc. The label says they are indicated for the treatment of major depressive disorder in adults. The medicine has been studied in short-term controlled trials for major depression, and the label also describes longer-term studies for helping maintain an antidepressant response.

The label includes a boxed warning about suicidal thinking and behavior in children, adolescents, and young adults taking antidepressants. It says patients of all ages should be watched closely for clinical worsening, suicidality, or unusual behavior changes, especially when treatment starts or the dose changes.

The label also warns about serotonin syndrome, sustained increases in blood pressure, angle-closure glaucoma risk in people with narrow angles, and possible sexual side effects. Venlafaxine tablets should not be used with MAOIs in the situations described in the label, and abrupt stopping can cause withdrawal-like symptoms, so dose changes should be done gradually when possible.

Storage Information

protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature] in a dry place. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). store venlafaxine tablets? Store venlafaxine tablets at room temperature between 68°F and 77°F (20°C to 25°C).

Key Counseling Points

• Take venlafaxine tablets exactly as prescribed.
• The label warns not to stop treatment suddenly because abrupt discontinuation can cause symptoms.
• Tell the prescriber about any unusual mood changes, worsening depression, or suicidal thoughts or behavior.
• Report symptoms that may suggest serotonin syndrome, such as agitation, hallucinations, fever, sweating, tremor, or diarrhea.
• Tell the prescriber about all medicines and supplements, especially MAOIs, linezolid, intravenous methylene blue, triptans, lithium, tramadol, buspirone, fentanyl, methadone, meperidine, or St. Johnu2019s Wort.
• Blood pressure should be monitored during treatment because venlafaxine can cause sustained increases in blood pressure.
• Tell the prescriber if there is a history of bipolar disorder or if manic or hypomanic symptoms appear.
• Report any eye symptoms promptly, since the label warns about angle-closure glaucoma in people with narrow angles.
• Ask about sexual side effects if they occur, because the label says SNRIs may cause changes in sexual function.
• The label says to use the smallest quantity of tablets consistent with good patient management to help reduce overdose risk.

Helpful Patient Education

Venlafaxine tablets, USP are a prescription antidepressant used for the treatment of major depressive disorder. This DailyMed label information includes key safety warnings, including the need to monitor for suicidal thoughts or behavior, serotonin syndrome, blood pressure changes, and symptoms that may occur if the medicine is stopped too quickly.

Educational product pages for venlafaxine hydrochloride tablets should also note important use limitations and precautions described in the label, such as contraindications with certain MAOIs and the need to watch for unusual changes in mood, behavior, or physical symptoms during treatment.

Medication Summary last generated: 2026-06-19 07:16:10